News

Decision Resources report: Nucynta as effective as immediate-release oxycodone

BY Alaric DeArment

WALTHAM, Mass. Most surveyed physicians who have prescribed a dual-acting opioid painkiller made by Johnson & Johnson consider it to have comparable efficacy to oxycodone, according to a report released Monday by market research firm Decision Resources.

The report, titled “Biologics and Formulations for Inflammatory and Nociceptive Pain: Will These Agents Gain Widespread Physician and Payer Acceptance Despite a Crowded Market?” found that 82% of the physicians found J&J subsidiary Ortho-McNeil’s Nucynta (tapentadol) as effective as immediate-release oxycodone, while 36% said it was more tolerable in terms of such side effects common among opioids as nausea and vomiting.

“Our survey results indicate that chronic low back pain and osteoarthritis pain patients would be in the populations most likely to be treated with tanezumab,” Decision Resources analyst Natalie Taylor said. “However, 46% of surveyed pain specialists, 23% of surveyed rheumatologists and 70% of surveyed [primary-care physicians] said that they do not expect to prescribe a biologic if it launches.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Boehringer Ingelheim’s cancer drug may be ‘next generation’ treatment

BY Alaric DeArment

RIDGEFIELD, Conn. Data from a late-stage clinical trial of an investigational drug by Boehringer Ingelheim could show that the drug is a “next generation” treatment for cancers of the lungs, head and neck, BI said Friday.

The German drug maker plans to present results of a phase 3 trial of BIBW 2992 at the annual meeting of the American Society of Clinical Oncology in Chicago, which will take place between June 4 and 8.

BIBW 2992 is a pharmaceutical drug that targets the epidermal growth factor receptor and human epidermal receptor 2, also known as EGFR and HER2. Both are proteins that are known to promote the growth of cancer cells. BI said the drug shrank tumors in 22% of head and neck cancer patients, compared with 13% among those taking Eli Lilly’s and Bristol-Myers Squibb’s Erbitux (cetuximab).

The company also reported that the drug showed “significant” ability to fight tumors in patients with non-small cell lung cancer, and that 61% of patients with EGFR mutations had significant tumor shrinkage.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

News

Americans need more faith… in fiber

BY Michael Johnsen

WHAT IT MEANS AND WHY IT’S IMPORTANT Not eating enough fiber doesn’t kill you. But the disease states that result from a poor fiber diet do. Not a believer? Then you too may be a victim of IDS (irrational disbelief syndrome), the tongue-in-cheek faux condition that Fiber One touts as being the No. 1 cause behind America’s lack of fiber faith.

(THE NEWS: Lack of fiber in Americans’ diet caused by negative perception, Mintel finds. For the full story, click here)

The IDS condition may have been created out the mind of a General Mills marketer, but the lack of fiber in the typical American’s diet is real. As are the disease states that fiber deficiency can trigger such disease states as cardiovascular disease, colorectal and esophageal cancer, obesity, atherosclerosis, and coronary heart disease. A number of other less severe conditions is also correlated with a low fiber intake — elevated cholesterol levels, hemorrhoids, constipation, diarrhea and flatulence.

The real conclusion you can draw from this study is that Americans don’t know what they don’t know — fiber doesn’t taste good; only people suffering from digestive issues need to supplement their diets with fiber; all fibers are created equal. False, false and false. And that spells opportunity for a whole host of manufacturers in moving the needle around fiber education.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES